First-Line Antiretroviral Drug Discontinuations in Children

Hdl Handle:
http://hdl.handle.net/10144/618811
Title:
First-Line Antiretroviral Drug Discontinuations in Children
Authors:
Fortuin-de Smidt, M; de Waal, R; Cohen, K; Technau, KG; Stinson, K; Maartens, G; Boulle, A; Igumbor, EU; Davies, MA
Journal:
PloS One
Abstract:
There are a limited number of paediatric antiretroviral drug options. Characterising the long term safety and durability of different antiretrovirals in children is important to optimise management of HIV infected children and to determine the estimated need for alternative drugs in paediatric regimens. We describe first-line antiretroviral therapy (ART) durability and reasons for discontinuations in children at two South African ART programmes, where lopinavir/ritonavir has been recommended for children <3 years old since 2004, and abacavir replaced stavudine as the preferred nucleoside reverse transcriptase inhibitor in 2010.
Publisher:
Public Library of Science
Issue Date:
13-Feb-2017
URI:
http://hdl.handle.net/10144/618811
DOI:
10.1371/journal.pone.0169762
PubMed ID:
28192529
Submitted date:
2017-02-27
Language:
en
ISSN:
1932-6203
Appears in Collections:
HIV/AIDS

Full metadata record

DC FieldValue Language
dc.contributor.authorFortuin-de Smidt, Men
dc.contributor.authorde Waal, Ren
dc.contributor.authorCohen, Ken
dc.contributor.authorTechnau, KGen
dc.contributor.authorStinson, Ken
dc.contributor.authorMaartens, Gen
dc.contributor.authorBoulle, Aen
dc.contributor.authorIgumbor, EUen
dc.contributor.authorDavies, MAen
dc.date.accessioned2017-02-28T21:21:07Z-
dc.date.available2017-02-28T21:21:07Z-
dc.date.issued2017-02-13-
dc.date.submitted2017-02-27-
dc.identifier.citationFirst-Line Antiretroviral Drug Discontinuations in Children. 2017, 12 (2):e0169762 PLoS ONEen
dc.identifier.issn1932-6203-
dc.identifier.pmid28192529-
dc.identifier.doi10.1371/journal.pone.0169762-
dc.identifier.urihttp://hdl.handle.net/10144/618811-
dc.description.abstractThere are a limited number of paediatric antiretroviral drug options. Characterising the long term safety and durability of different antiretrovirals in children is important to optimise management of HIV infected children and to determine the estimated need for alternative drugs in paediatric regimens. We describe first-line antiretroviral therapy (ART) durability and reasons for discontinuations in children at two South African ART programmes, where lopinavir/ritonavir has been recommended for children <3 years old since 2004, and abacavir replaced stavudine as the preferred nucleoside reverse transcriptase inhibitor in 2010.en
dc.language.isoenen
dc.publisherPublic Library of Scienceen
dc.rightsPublished by Public Library of Science, [url]http://www.plosone.org/[/url] Archived on this site by Open Access permissionen
dc.titleFirst-Line Antiretroviral Drug Discontinuations in Childrenen
dc.identifier.journalPloS Oneen

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.